Item 1.01 Entry into a Material Definitive Agreement





Merger Agreement


On November 8, 2022, Murphy Canyon Acquisition Corp., a Delaware corporation ("MURF"), entered into an agreement and plan of merger (the "Merger Agreement") by and among MURF, Conduit Pharmaceuticals Limited, a Cayman Islands exempted company ("Conduit") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of MURF ("Merger Sub"). MURF and Merger Sub are sometimes referred to collectively as the "MURF Parties." Pursuant to the Merger Agreement, a business combination between MURF and Conduit will be effected through the merger of Merger Sub with and into Conduit, with Conduit surviving the merger as a wholly owned subsidiary of MURF (the "Merger"). Upon the closing of the Merger (the "Closing"), it is anticipated that MURF will change its name to "Conduit Pharmaceuticals Inc." The board of directors of MURF has (i) approved and declared advisable the Merger Agreement, the Ancillary Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement and related transactions by the stockholders of MURF.

The Merger is expected to be consummated in the first quarter of 2023, following the receipt of the required approval by the stockholders of MURF and the shareholders of Conduit and the satisfaction of certain other customary closing conditions.





Merger Consideration



The total consideration to be paid at Closing (the "Merger Consideration") by MURF to the Conduit shareholders will be six hundred and fifty million dollars ($650,000,000) and will be payable in shares of Class A common stock, par value $0.0001 per share, of MURF ("MURF Common Stock"). The number of shares of MURF Common Stock to be paid to the shareholders of Conduit as Merger Consideration will be 65,000,000, with each share being valued at $10.00. All cash proceeds remaining in the trust will be used to pay transaction costs and as growth capital for MURF.

At the signing of the Merger Agreement, there were 2,000 ordinary shares, with a par value of GBP0.0001 per share (the "Conduit Ordinary Shares"), issued and outstanding. Each Conduit Ordinary Share issued and outstanding, and all convertible debt issued and outstanding, immediately prior to the consummation of the Merger (other than any dissenting shares) shall be exchanged for and otherwise converted into the right to receive the applicable Merger Consideration per share pursuant to the Merger Agreement. The effective date and time of the Merger is referred to in the Merger Agreement as the effective time (the "Effective Time").

Representations and Warranties

The Merger Agreement contains customary representations and warranties of Conduit with respect to, among other things: (i) corporate existence and power; (ii) organizational documents; (iii) capitalization; (iv) authorization to enter into the Merger Agreement and related transactions; (v) no conflicts and non-contravention; (vi) permits and compliance; (vii) financial statements; (viii) no undisclosed liabilities; (ix) absence of certain changes; (x) absence of litigation; (xi) employee benefit plans; (xii) labor matters; (xiii) real property and title to assets; (xiv) intellectual property; (xv) taxes; (xvi) environmental matters; (xvii) material contracts; (xviii) customers and suppliers; (xix) insurance; (xx) internal controls; (xxi) accuracy of statements; (xxii) COVID-19 matters; (xxiii) delivery of support agreement; (xxiv) board approval; (xxv) brokers and finders' fees; (xxvi) takeover laws; (xxvii) international trade matters and anti-bribery compliance; (xxiii) that Conduit is not an investment company; (xxix) withholding; (xxx) exclusivity of representations and warranties; and (xxxi) full disclosure.

The Merger Agreement contains customary representations and warranties of the MURF Parties with respect to, among other things: (i) corporate existence and power; (ii) organizational documents; (iii) capitalization; (iv) authorization to enter into the Merger Agreement and related transactions; (v) no conflicts and non-contravention; (vi) compliance; (vii) MURF publicly filed documents and financial statements; (viii) absence of certain changes; (ix) absence of litigation; (x) board approval; (xi) no prior operations of Merger Sub; (xii) amount in the trust account; (xiii) employees; (xiv) taxes; (xv) listing of MURF securities; (xvi) that MURF is not an investment company; (xvii) statements in public filings; (xviii) contracts; (xix) brokers and finders' fees; (xx) delivery of support agreement; (xxi) MURF and Merger Sub's investigation and reliance; and (xxii) full disclosure.

All representations and warranties by all parties terminate upon the Effective Time, and no representations, warranties, covenants, obligations or other agreements contained in the Merger Agreement survive the Effective Time.





Covenants


The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement on Form S-4 (the "Registration Statement") and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of MURF's stockholders. MURF has also agreed to include in the Proxy Statement the recommendation of its board that its stockholders approve all of the proposals to be presented at the special meeting of MURF's stockholders that will be called in order to approve the Merger and related transactions (the "MURF Special Meeting").

Conduct between Signing and Closing

Each of MURF and Merger Sub has agreed that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate, encourage or engage in any negotiations with any party relating to an alternative transaction, take any action intended to facilitate an alternative transaction or approve, recommend or enter into any agreement relating to an alternative transaction. MURF and Conduit also have agreed, subject to certain exceptions, to operate their respective companies in the ordinary course through the Closing Date.





Conditions to Closing



The consummation of the Merger is conditioned upon, among other things, (i) the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions; (ii) the Registration Statement becoming effective under the Securities Act of 1933, as amended (the "Securities Act"); (iii) the approval by MURF's stockholders of the Merger and related transactions; (iv) the approval by Conduit's shareholders of the Merger and related transactions; (v) the aggregate cash available to MURF at the Closing (after giving effect to any redemptions by MURF's stockholders and the payment of all authorized transaction expenses) being at least $27,000,000; (vi) all Ancillary Agreements having been executed by all parties thereto; and (vii) all required filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any other governmental authority having been completed and cleared.

Solely with respect to the MURF Parties, the consummation of the Merger is conditioned upon, among other things: (i) Conduit having duly performed or complied with all of its obligations under the Merger Agreement in all material respects; (ii) the representations and warranties of Conduit being true and correct in all material respects; (iii) no event having occurred that would result in a Company Material Adverse Effect (as defined in the Merger Agreement); (iv) Conduit providing MURF a certificate from an authorized officer of Conduit as to the accuracy of the foregoing conditions; (v) after giving effect to the Merger, MURF shall have at least $5,000,001 in net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act); (vi) MURF and Conduit having cooperated in good faith to negotiate and execute new employment agreements with David Tapolczay and Adam Sragovicz, the current Chief Financial Officer and a director of MURF; and (vii) certain intellectual property having been assigned to Conduit UK Management Ltd, an entity that will be a wholly-owned subsidiary of Conduit as of the consummation of the Merger.

Solely with respect to Conduit, the consummation of the Merger is conditioned upon, among other things: (i) the MURF Parties having duly performed or complied with all of their obligations under the Merger Agreement in all material respects; (ii) the representations and warranties of the MURF Parties being true and correct in all material respects; (iii) no event having occurred that would result in an Murphy Material Adverse Effect (as defined in the Merger Agreement; and (iv) each of the MURF Parties providing Conduit a certificate from an authorized officer as to the accuracy of the foregoing conditions.





Termination


The Merger Agreement may be terminated as follows:





  (i)   By the mutual consent of MURF and Conduit;

  (ii)  by MURF, if any of the representations or warranties of Conduit set forth
        in the Merger Agreement is not true and correct, or if Conduit has failed
. . .

Item 3.02. Unregistered Sales of Equity Securities.

The disclosure set forth above in Item 1.01 of this Form 8-K under the heading "Subscription Agreement" is incorporated by reference herein. The securities issuable in connection with the Private Placement will not be registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.

Item 9.01. Financial Statements and Exhibits.




Exhibit No.   Description
2.1             Merger Agreement dated as of November 8, 2022, by and among Murphy
              Canyon Acquisition Corp., Conduit Merger Sub, Inc. and Conduit
              Pharmaceuticals Limited
4.1             Form of Warrant
10.1            Form of Subscription Agreement
10.2            Form of Lock-Up Agreement
10.3            Sponsor Support Agreement dated as of November 8, 2022, by and
              among Murphy Canyon Acquisition Corp. and each of the Persons set
              forth on Schedule I attached thereto
10.4            Shareholder Support Agreement dated as of November 8, 2022, by and
              among Murphy Canyon Acquisition Corp., Conduit Pharmaceuticals
              Limited and each of the Persons set forth on Schedule I attached
              thereto.
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses